Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it ...

KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader KT-474. This setback was somewhat offset by KYMR’s announcement of an exclusive option and license ...

Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...

Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...

Trafficking and exploitation can be a blind spot for business leaders, putting employees at risk and exposing the ...

Given that there is no confirmed CDC director and a small newly appointed panel with many members lacking a broad vaccine or immunology knowledge, “there are concerns about the rushed nature of this ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 ...

FOSTER CITY, CA & WATERTOWN, MA, USA I June 25, 2025 I Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced ...

Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the ...